Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): A randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 856-861

  Koeberle, D ^a,m   Dufour, J F ^b   Demeter, G ^c   Li, Q ^d   Ribi, K ^e   Samaras, P ^f   Saletti, P ^g   Roth, A D ^h   Horber, D ^a   Buehlmann, M ^b   Wagner, A D ⁱ   Montemurro, M ^g,i   Lakatos, G ^c   Feilchenfeldt, J ^j   Peck Radosavljevic, M ^k   Rauch, D ^l   Tschanz, B ^d   Bodoky, G ^c  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c St László Teaching Hospital   (Hungary)

^d SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^e International Breast Cancer Study Group   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁱ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^j Hôpital du Valais RSV CHCVs   (Switzerland)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l Sonnenhof Spital AG   (Switzerland)

^m Claraspital Basel   (Switzerland)

more..

Author keywords

Everolimus; Hepatocellular carcinoma; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; EVEROLIMUS; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER GROWTH; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADVERSE DRUG REACTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVEROLIMUS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84964786369     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw054     Document Type: Article

References (22)

1. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
2. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Hollebecque A, Malka D, Ferté C et al. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer 2015; 51: 327-339.
4. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072-2079.
5. Shibata T, Aburatani H. Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 2014; 11(6): 340-349.
6. Totoki Y, Tatsuno K, Covington KR et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014; 46: 1267-1273.
7. Huynh H, Chow KH, Soo KC et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009; 13: 1371-1380.
8. Wang Z, Zjou J, Qiu SJ et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res 2008; 14: 5124-5130.
9. Piguet AC, Saar B, Hlushchuk R et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 1007-1017.
10. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
11. Giessinger S, Amato RJ, Jac J et al. A phase I study with a daily regimen of the oral mTOR inhibitor RAD001 (Everolimus) plus sorafenib for patients with metastatic renal cell cancer (MRCC). Proc Am Soc Clin Oncol 2008; Abstr. 14603.
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
14. Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25: 1753-1759.
15. Steel JL, Eton DT, Cella D et al. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 2006; 17: 304-312.
16. Butow P, Coates A, Dunn S et al. On the receiving end. IV: Validation of quality of life indicators. Ann Oncol 1991; 2: 597-603.
17. Bernhard J, Maibach R, Thurlimann B et al. Patients' estimation of overall treatment burden: why not ask the obvious? J Clin Oncol 2002; 20: 65-72.
18. A' Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-866.
19. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011; 117: 5094-5102.
20. Finn RS, Poon RT, Yau T et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013; 59: 1271-1277.
21. Zhu AX, Kudo M, Assenat E et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57-67.
22. Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 2014; 6: 776-782.